STERIS plc (NYSE:STE) Shares Acquired by Alliance Wealth Advisors LLC UT

Alliance Wealth Advisors LLC UT increased its stake in STERIS plc (NYSE:STE) by 6.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,241 shares of the medical equipment provider’s stock after purchasing an additional 207 shares during the quarter. Alliance Wealth Advisors LLC UT’s holdings in STERIS were worth $666,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Franklin Resources Inc. boosted its stake in shares of STERIS by 171.2% during the 3rd quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider’s stock worth $191,370,000 after acquiring an additional 529,308 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in STERIS by 7,418.7% during the third quarter. Assenagon Asset Management S.A. now owns 309,771 shares of the medical equipment provider’s stock worth $75,132,000 after purchasing an additional 305,651 shares in the last quarter. Boston Trust Walden Corp boosted its position in STERIS by 400.4% during the fourth quarter. Boston Trust Walden Corp now owns 224,741 shares of the medical equipment provider’s stock worth $46,198,000 after purchasing an additional 179,829 shares in the last quarter. Swedbank AB purchased a new stake in STERIS during the third quarter worth $28,251,000. Finally, Benjamin Edwards Inc. grew its holdings in STERIS by 2,123.2% in the third quarter. Benjamin Edwards Inc. now owns 113,672 shares of the medical equipment provider’s stock valued at $27,574,000 after purchasing an additional 108,559 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Insider Buying and Selling

In other news, SVP Cary L. Majors sold 1,682 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the completion of the sale, the senior vice president now directly owns 11,372 shares in the company, valued at $2,471,363.04. This represents a 12.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.14% of the stock is currently owned by company insiders.

STERIS Trading Up 0.5 %

Shares of STERIS stock opened at $219.53 on Wednesday. The firm has a market cap of $21.67 billion, a PE ratio of 50.12 and a beta of 0.84. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. STERIS plc has a fifty-two week low of $197.82 and a fifty-two week high of $248.24. The business’s fifty day moving average is $212.26 and its two-hundred day moving average is $224.61.

STERIS (NYSE:STE) last issued its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The firm had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same period last year, the company earned $2.03 EPS. The firm’s quarterly revenue was up 7.3% on a year-over-year basis. Analysts anticipate that STERIS plc will post 9.11 earnings per share for the current year.

STERIS Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Investors of record on Thursday, February 20th will be issued a $0.57 dividend. The ex-dividend date is Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a yield of 1.04%. STERIS’s payout ratio is 52.05%.

Analyst Ratings Changes

A number of equities research analysts recently commented on STE shares. StockNews.com cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Piper Sandler raised their price objective on shares of STERIS from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a research note on Monday, November 18th. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research report on Friday, November 8th. Finally, Stephens restated an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $263.75.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.